Description
Apelin-36 is the full-length mature peptide produced from the translated 77 amino acid prepropeptide. The apelins act primarily in the peripheral and central nervous system, playing important roles in regulating cardiovascular function, fluid homeostasis, hypertension, and insulin sensitivity.1 Apelin-36 is a less potent agonist of APJ than either apelin-17 or apelin-13 (EC50 = 20, 2.5, and 0.37 nM, respectively).2,3 Apelin-36 potently inhibits HIV-1 entry into cells expressing APJ and CD4, limiting HIV infection.4WARNING This product is not for human or veterinary use.
References
[1] MATTHIAS J. KLEINZ Anthony P D. Emerging roles of apelin in biology and medicine[J]. Pharmacology & Therapeutics, 2005, 107 2: Pages 198-211. DOI:
10.1016/j.pharmthera.2005.04.001[2] KAZUHIKO TATEMOTO . Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor[J]. Biochemical and biophysical research communications, 1998, 251 2: Pages 471-476. DOI:
10.1006/bbrc.1998.9489[3] DENNIS K. LEE. Characterization of Apelin, the Ligand for the APJ Receptor[J]. Journal of Neurochemistry, 2001, 74 1: 34-41. DOI:
10.1046/j.1471-4159.2000.0740034.x[4] MIN-XU ZOU. Apelin peptides block the entry of human immunodeficiency virus (HIV)[J]. FEBS Letters, 2000, 473 1: 15-18. DOI:
10.1016/s0014-5793(00)01487-3
